GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Quick Ratio

CLGN (CollPlant Biotechnologies) Quick Ratio : 5.23 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. CollPlant Biotechnologies's quick ratio for the quarter that ended in Sep. 2024 was 5.23.

CollPlant Biotechnologies has a quick ratio of 5.23. It generally indicates good short-term financial strength.

The historical rank and industry rank for CollPlant Biotechnologies's Quick Ratio or its related term are showing as below:

CLGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.81   Med: 3.35   Max: 18.58
Current: 5.23

During the past 12 years, CollPlant Biotechnologies's highest Quick Ratio was 18.58. The lowest was 0.81. And the median was 3.35.

CLGN's Quick Ratio is ranked better than
63.61% of 1503 companies
in the Biotechnology industry
Industry Median: 3.41 vs CLGN: 5.23

CollPlant Biotechnologies Quick Ratio Historical Data

The historical data trend for CollPlant Biotechnologies's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Quick Ratio Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 1.30 14.60 9.74 8.40

CollPlant Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.28 8.40 6.96 6.14 5.23

Competitive Comparison of CollPlant Biotechnologies's Quick Ratio

For the Biotechnology subindustry, CollPlant Biotechnologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Quick Ratio distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Quick Ratio falls into.



CollPlant Biotechnologies Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

CollPlant Biotechnologies's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(28.022-0.714)/3.251
=8.40

CollPlant Biotechnologies's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(16.497-0.454)/3.069
=5.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CollPlant Biotechnologies  (NAS:CLGN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


CollPlant Biotechnologies Quick Ratio Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.